For the researchers from the UK and other countries, BPC-157 is still an interesting experimental peptide that helps to gain new knowledge about the peptide biology, not an established treatment.
Human clinical data is limited
This makes it the preferred choice for injuries, inflammation, or vascular healing outside the gut
AOD-9604 was developed to: Stimulate lipolysis (breakdown of stored fat) Inhibit lipogenesis (formation of new fat) Avoid raising IGF-1 levels Reduce impact on blood glucose Because it is a small fragment rather than the full hormone, it theoretically targets fat metabolism more specifically
Cysteamine colitis In general, the controls could not heal cysteamine colitis and colon-colon anastomosis
Sometimes, they go a bit too far, creating excessive inflammation